A citation-based method for searching scientific literature

Jonathan D Schofield, Yifen Liu, Prasanna Rao-Balakrishna, Rayaz A Malik, Handrean Soran. Diabetes Ther 2016
Times Cited: 132







List of co-cited articles
305 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Dyslipidemia in type 2 diabetes mellitus.
Arshag D Mooradian. Nat Clin Pract Endocrinol Metab 2009
512
10

IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.
N H Cho, J E Shaw, S Karuranga, Y Huang, J D da Rocha Fernandes, A W Ohlrogge, B Malanda. Diabetes Res Clin Pract 2018
8

Diabetic dyslipidemia.
Liya Wu, Klaus G Parhofer. Metabolism 2014
190
7

Oxidative stress and diabetic complications.
Ferdinando Giacco, Michael Brownlee. Circ Res 2010
7


Pathophysiology of Diabetic Dyslipidemia.
Tsutomu Hirano. J Atheroscler Thromb 2018
110
6

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
6



Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
P M Kearney, L Blackwell, R Collins, A Keech, J Simes, R Peto, J Armitage, C Baigent. Lancet 2008
5

Association between insulin resistance and the development of cardiovascular disease.
Valeska Ormazabal, Soumyalekshmi Nair, Omar Elfeky, Claudio Aguayo, Carlos Salomon, Felipe A Zuñiga. Cardiovasc Diabetol 2018
374
5

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
5


Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
5


Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management.
Joe M Chehade, Margaret Gladysz, Arshag D Mooradian. Drugs 2013
113
4

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, S Kaptoge, E Di Angelantonio, E Ingelsson, D A Lawlor, E Selvin, M Stampfer,[...]. Lancet 2010
4

Metabolic origins and clinical significance of LDL heterogeneity.
Kaspar K Berneis, Ronald M Krauss. J Lipid Res 2002
566
4

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
4

Diabetes mellitus and oxidative stress-A concise review.
Ullah Asmat, Khan Abad, Khan Ismail. Saudi Pharm J 2016
452
4

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
4

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
4

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Pouya Saeedi, Inga Petersohn, Paraskevi Salpea, Belma Malanda, Suvi Karuranga, Nigel Unwin, Stephen Colagiuri, Leonor Guariguata, Ayesha A Motala, Katherine Ogurtsova,[...]. Diabetes Res Clin Pract 2019
4

Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.
Yan Zheng, Sylvia H Ley, Frank B Hu. Nat Rev Endocrinol 2018
4

Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms.
John R Petrie, Tomasz J Guzik, Rhian M Touyz. Can J Cardiol 2018
330
4

Mechanisms of diabetic complications.
Josephine M Forbes, Mark E Cooper. Physiol Rev 2013
3


Treatment of dyslipidemia in patients with type 2 diabetes.
Krishnaswami Vijayaraghavan. Lipids Health Dis 2010
58
5

Antidiabetic activity of Aloe vera L. juice. I. Clinical trial in new cases of diabetes mellitus.
S Yongchaiyudha, V Rungpitarangsi, N Bunyapraphatsara, O Chokechaijaroenporn. Phytomedicine 1996
73
4



Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases.
Teresa Vanessa Fiorentino, Annamaria Prioletta, Pengou Zuo, Franco Folli. Curr Pharm Des 2013
357
3




Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
3

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
3

Prevalence and Risk Factors Associated with Dyslipidemia in Chongqing, China.
Li Qi, Xianbin Ding, Wenge Tang, Qin Li, Deqiang Mao, Yulin Wang. Int J Environ Res Public Health 2015
50
6

The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital.
Amit Kumar Dixit, Ranjit Dey, Aela Suresh, Siddhartha Chaudhuri, Ashok Kumar Panda, Achintya Mitra, Jayram Hazra. J Diabetes Metab Disord 2014
21
14

Dyslipidemia in obesity: mechanisms and potential targets.
Boudewijn Klop, Jan Willem F Elte, Manuel Castro Cabezas. Nutrients 2013
552
3

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Helen M Colhoun, D John Betteridge, Paul N Durrington, Graham A Hitman, H Andrew W Neil, Shona J Livingstone, Margaret J Thomason, Michael I Mackness, Valentine Charlton-Menys, John H Fuller. Lancet 2004
3

Future perspectives of the pharmacological management of diabetic dyslipidemia.
Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Manfredi Rizzo, Ali A Rizvi. Expert Rev Clin Pharmacol 2019
12
25





New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
Marja-Riitta Taskinen, Jan Borén. Atherosclerosis 2015
207
3

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
3

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A Keech, R J Simes, P Barter, J Best, R Scott, M R Taskinen, P Forder, A Pillai, T Davis, P Glasziou,[...]. Lancet 2005
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.